<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533949</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG 0617</org_study_id>
    <secondary_id>CDR0000564240</secondary_id>
    <secondary_id>NCCTG-N0628</secondary_id>
    <secondary_id>CALGB-30609</secondary_id>
    <secondary_id>NCI-2013-01762</secondary_id>
    <nct_id>NCT00533949</nct_id>
  </id_info>
  <brief_title>High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy With Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
      chemotherapy, such as paclitaxel, carboplatin work in different ways to stop the growth of
      tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal
      antibodies, such as cetuximab can block tumor growth in different ways. Some block the
      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
      carry tumor-killing substances to them. It is not yet known whether high-dose radiation
      therapy is more effective than standard-dose radiation therapy when given together with
      combination chemotherapy with or without cetuximab in treating patients with non-small cell
      lung cancer.

      PURPOSE: This randomized phase III trial is studying high-dose or standard-dose radiation
      therapy given together with chemotherapy with or without cetuximab to see how well they work
      in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be
      removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the overall survival of patients with newly diagnosed, unresectable stage
           IIIA or IIIB non-small cell lung cancer treated with high- versus standard-dose
           conformal radiotherapy with concurrent and consolidation chemotherapy comprising
           carboplatin and paclitaxel.

        -  To compare the overall survival of patients treated with versus without cetuximab in the
           setting of concurrent chemotherapy

      Secondary

        -  To compare progression-free survival and local-regional tumor control in patients
           treated with these regimens.

        -  To compare the toxicity of high- versus standard-dose conformal radiotherapy and
           concurrent chemotherapy with versus without cetuximab in these patients.

        -  To investigate the prognostic and predictive effects of gross tumor volume on overall
           survival of patients treated with these regimens.

        -  To compare the quality of life of patients treated with these regimens.

        -  To correlate outcomes (i.e., survival, toxicity, or QOL) in these patients with
           biological parameters.

        -  To analyze the predictive value of pre-treatment standardized uptake value (SUV) of
           positron emission tomography (PET) scan in predicting survival, distant metastasis, and
           local-regional control in patients treated with these regimens.

        -  To explore biological markers to predict clinical outcome including survival, distant
           metastasis, local-regional control, and QOL (including toxicity) in patients treated
           with these regimens.

        -  To prospectively collect and bank tissue, blood, and urine specimens for future
           biomarker analyses in predicting clinical outcome in patients treated with these
           regimens.

        -  To investigate associations between epidermal growth factor receptor (EGFR) expression
           and toxicity, response, overall survival, and progression-free survival.

      OUTLINE: This is a multicenter study. Patients are stratified according to PET staging (yes
      vs no), radiotherapy technique (3-dimensional conformal radiotherapy vs intensity-modulated
      radiotherapy), Zubrod performance status (0 vs 1), and histology (squamous vs non-squamous).
      Patients are randomized to 1 of 4 treatment arms. (Arms II and IV closed to accrual effective
      6/17/11)

        -  Arm I: Patients undergo standard dose radiotherapy 5 days a week for 6 weeks for a total
           of 60 Gy. Patients receive concurrent chemotherapy comprising paclitaxel IV over 1 hour
           and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Patients also
           receive consolidation treatment of paclitaxel and carboplatin on days 64 and 85.

        -  Arm II: Patients undergo high-dose radiotherapy 5 days per week for 7.5 weeks. Patient
           also receive concurrent paclitaxel and carboplatin as in Arm I on days 1, 8, 15, 22, 29,
           36, and 43 . Patients also receive consolidation treatment comprising paclitaxel and
           carboplatin on days 71 and 92. (closed to accrual effective 6/17/11)

        -  Arm III: Patients undergo standard-dose radiotherapy 5 days a week for 6 weeks for a
           total of 60 Gy. Patients receive cetuximab in addition to concurrent chemotherapy as in
           Arm I. Treatment continues with chemoradiation and cetuximab on days 8, 15, 22, 29, 36,
           and 43. Patients receive consolidation treatment of cetuximab on days 50, 57, 64, 71,
           78, 85, 92, 99, and 106 and paclitaxel and carboplatin on days 71 and 92.

        -  Arm IV: Patients undergo high-dose radiotherapy 5 days a week for 7.5 weeks for a total
           of 74 Gy. Patients receive cetuximab in addition to concurrent chemotherapy as in Arm I.
           Treatment continues with chemoradiation and cetuximab on days 8, 15, 22, 29, 36, 43, and
           50. Patients receive consolidation treatment of cetuximab on days 57, 64, 71, 78, 85,
           92, 99, 106, and 113 and paclitaxel and carboplatin on days 78 and 99. (closed to
           accrual effective 6/17/11)

      Patients may undergo tumor tissue, blood, and urine collection periodically during study for
      tissue banking or biomarker correlative studies.

      Patients may undergo quality-of-life assessment at baseline and periodically during study.

      After completion of study therapy, patients are followed periodically for 5 years and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study was revised 06/18/08 to a 2x2 factorial design to evaluate the addition of cetuximab to the radiation therapy regimens.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Analysis occurs after 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
    <description>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Analysis occurs after 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
    <description>A failure for progression-free survival (PFS) is the first occurrence of local or regional progression, distant metastases, or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions. Time is measured from the date of randomization to the date of first failure. Patients without failure are censored at the date of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional Failure (Reported as Two-year Estimates)</measure>
    <time_frame>Analysis occurs after 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
    <description>A failure for local-regional failure is the first occurrence of local or regional progression. Time is measured from the date of randomization to the date of first failure. Patients alive without local or regional failure at the time of last follow-up are censored. Patients who died without local or regional failure are considered as having competing risk at the time of death. Local-regional failure was estimated by the cumulative incidence method and 2 year estimates are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 3-5 Esophagitis and Pneumonitis Adverse Events as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0</measure>
    <time_frame>Analysis occurs after 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
    <description>Treatment-related esophagitis and pneumonitis were assessed graded using the CTCAE v3.0. Comparisons are only made between radiation therapy dosing levels because the cetuximab regimen was known to be safe in combination with radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Other Grade 3-5 Adverse Events as Assessed by NCI CTCAE v3.0</measure>
    <time_frame>Analysis occurs 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
    <description>Treatment-related adverse events other than esophagitis and pneumonitis were assessed graded using the CTCAE v3.0. Comparisons are only made between radiation therapy dosing levels because the cetuximab regimen was known to be safe in combination with radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death During or Within 30 Days of Discontinuation of Protocol Treatment</measure>
    <time_frame>From start of treatment to 24 months.</time_frame>
    <description>Deaths regardless of cause and occuring during or within 30 days of discontinuation of protocol treatment were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Decline From Baseline to 3 Months in the Lung Cancer Subscale (LCS) of the Functional Assessment of the Cancer Therapy Trial Outcome Index (FACT-TOI).</measure>
    <time_frame>At baseline and 3 months.</time_frame>
    <description>A decline of 2 points in the LCS from baseline to 3 months was considered a clinically meaningful change indicating a decline in quality of life. Comparisons are only made between radiation therapy dosing levels because the cetuximab regimen was known to be safe in combination with radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Swallowing Ability</measure>
    <time_frame>From start of treatment to 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-adjusted Survival Based on EuroQoL (EQ5D)-Derived Health Utility Score</measure>
    <time_frame>From start of treatment to 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Tumor Markers With Overall Survival, Local-regional Failure, and QOL</measure>
    <time_frame>Analysis occurs after 339 deaths have been reported, estimated at 5.6 years from start of study, unless a futility bound is crossed prior to that.</time_frame>
    <description>Biomarker data has not yet been obtained and therefore this outcome measure cannot yet be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic and Predictive Effects of Gross Tumor Volume on Overall Survival</measure>
    <time_frame>From randomization to date of death or last follow-up. Analysis occurs after 339 deaths have been reported.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic Value of Pre-treatment Standardized Uptake Value (SUV) of Positron Emission Tomography (PET) Scan in Predicting Survival, Distant Metastasis, and Local-regional Control</measure>
    <time_frame>From randomization to date of failure (either local or regional), death or last follow-up. Analysis occurs after 339 deaths have been reported.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">544</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Radiation Toxicity</condition>
  <arm_group>
    <arm_group_label>60 Gy RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>74 Gy RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 Gy RT + Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>74 Gy RT + Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.</description>
    <arm_group_label>60 Gy RT + Cetuximab</arm_group_label>
    <arm_group_label>74 Gy RT + Cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.
Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22.</description>
    <arm_group_label>60 Gy RT</arm_group_label>
    <arm_group_label>74 Gy RT</arm_group_label>
    <arm_group_label>60 Gy RT + Cetuximab</arm_group_label>
    <arm_group_label>74 Gy RT + Cetuximab</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.
Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22.</description>
    <arm_group_label>60 Gy RT</arm_group_label>
    <arm_group_label>74 Gy RT</arm_group_label>
    <arm_group_label>60 Gy RT + Cetuximab</arm_group_label>
    <arm_group_label>74 Gy RT + Cetuximab</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>60 Gy RT</intervention_name>
    <description>Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.</description>
    <arm_group_label>60 Gy RT</arm_group_label>
    <arm_group_label>60 Gy RT + Cetuximab</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>74 Gy RT</intervention_name>
    <description>Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.</description>
    <arm_group_label>74 Gy RT</arm_group_label>
    <arm_group_label>74 Gy RT + Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed newly diagnosed non-small cell lung cancer
             (NSCLC)

               -  Stage IIIA or IIIB disease

                    -  N3 supraclavicular disease or contralateral hilar lymph node involvement
                       (i.e. greater than 1.5 cm on short axis or positive on PET scan) not allowed

                    -  N2 or N3 disease and an undetectable NSCLC primary tumor allowed

               -  Unresectable or inoperable disease

          -  No distant metastases

          -  Pleural effusion allowed provided effusion is minimal and none of the following
             conditions are present:

               -  Cytologically positive pleural effusion detectable by CT scan and chest x-ray
                  (pleuracentesis required to confirm negative cytology of pleural fluid)

               -  Greater than minimal pleural effusions (minimal effusions not detectable by chest
                  x-ray and too small to tap safely are allowed)

               -  Exudative pleural effusions, regardless of cytology

               -  Malignant pleural effusion (T4 incurable disease)

          -  Measurable or evaluable disease

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-1

          -  Absolute neutrophil (ANC) ≥ 1,800 cells/mm³

          -  Platelet count ≥ 100,000 cells/mm³

          -  Hemoglobin ≥ 10.0 g/dL (transfusion or other intervention allowed)

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  Bilirubin normal

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 times upper
             limit of normal

          -  Pulmonary Function Test (PFTs) including forced expiratory volume at 1 sec. (FEV1) ≥
             1.2 L/sec or ≥ 50% predicted (best value obtained prior to or after use of
             bronchodilator)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective protection

          -  No uncontrolled neuropathy ≥ grade 2

          -  Patients with post-obstructive pneumonia allowed

          -  Patients must speak English or Spanish in order to complete the mandatory EORTC QLQ-30
             and PRO-CTCAE, which are only available in certain languages

          -  No prior invasive malignancy, except nonmelanoma skin cancer, carcinoma in situ of the
             breast, oral cavity, or cervix, unless the patient has been disease-free for the past
             3 years

          -  No prior severe infusion reaction to a monoclonal antibody

          -  No weight loss of ≥ 10% within the past 4 weeks

          -  No history of allergic reaction to paclitaxel or other taxanes, or to carboplatin

          -  No severe, active comorbidity, including any of the following:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the past 6 months

               -  Transmural myocardial infarction within the past 6 months

               -  Acute bacterial or fungal infection requiring IV antibiotics at the time of study
                  entry

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or within past 30 days precluding study therapy

               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

               -  AIDS

          -  No significant history of uncontrolled cardiac disease, including any of the
             following:

               -  Uncontrolled hypertension

               -  unstable angina

               -  Myocardial infarction within the past 6 months

               -  Uncontrolled congestive heart failure

               -  Cardiomyopathy with decreased ejection fraction

        PRIOR CONCURRENT THERAPY:

          -  At least 3 weeks since prior exploratory thoracotomy (if performed)

          -  Prior systemic chemotherapy allowed, provided it was not given for NSCLC

          -  No prior therapy that specifically and directly targets the EGFR pathway

          -  No prior radiotherapy to the region of NSCLC that would result in overlap of
             radiotherapy fields

          -  No concurrent white blood cell (WBC) growth factors (i.e., filgrastim [G-CSF] or
             sargramostim [GM-CSF]) given during radiotherapy or prophylactically during
             consolidation chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Bradley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mallinckrodt Institute of Radiology at Washington University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hak Choy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory A. Masters, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CCOP - Christiana Care Health Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven E. Schild, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex A. Adjei, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey A. Bogart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>State University of New York - Upstate Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur William Blackstock, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark A. Socinski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Blumenschein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ritsuko Komaki, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff Sloan, PhD, HSR</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Dobelbower, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tien Hoang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ken Forster, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Movsas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joe Y. Chang, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph O. Deasy, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy San Juan Medical Center</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enloe Cancer Center at Enloe Medical Center</name>
      <address>
        <city>Chico</city>
        <state>California</state>
        <zip>95926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center at John Muir Health - Concord Campus</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94524-4110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Agnes Cancer Center at Saint Agnes Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital Regional Cancer Center - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feather River Hospital Cancer Center</name>
      <address>
        <city>Paradise</city>
        <state>California</state>
        <zip>95969</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Center - Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiological Associates of Sacramento Medical Group, Incorporated</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Helena Hospital</name>
      <address>
        <city>Saint Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Cancer Center at Penrose Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80933</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Radiation Oncology</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Suburban Medical Center</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute at Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward General Medical Center Cancer Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network at Southside Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center South</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ella Milbank Foshay Cancer Center at Jupiter Medical Center</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist-South Miami Regional Cancer Program</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network - Orange Park</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Center - Palatka</name>
      <address>
        <city>Palatka</city>
        <state>Florida</state>
        <zip>32177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Cancer Center at Sacred Heart Hospital</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flagler Cancer Center</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center for Excellence at Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Crawford Long Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles B. Eberhart Cancer Center at DeKalb Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute at St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creticos Cancer Center at Advocate Illinois Masonic Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Center at Pekin Hospital</name>
      <address>
        <city>Pekin</city>
        <state>Illinois</state>
        <zip>61554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Medical Center of Illinois</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Associates Southwest</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Regional Cancer Center at Parkview Health</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care at Goshen General Hospital</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers - East</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Care at Community Hospital East</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Care at Community Hospital North</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at Ball Memorial Hospital</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303-3499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Regional Cancer Center at Mercy Medical Center</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Stoddard Cancer Center at Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy Medical Center - Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy Medical Center - North Iowa</name>
      <address>
        <city>Mason City</city>
        <state>Iowa</state>
        <zip>50401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology Associates, LLP</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503-9985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center Office of Clinical Research</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71315-3198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Bird Perkins Cancer Center - Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Ochsner</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Agnes Hospital Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shore Regional Cancer Center at Memorial Hospital - Easton</name>
      <address>
        <city>Easton</city>
        <state>Maryland</state>
        <zip>21601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Regional Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Regional Cancer Program at D'Amour Center for Cancer Care</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lacks Cancer Center at Saint Mary's Health Care</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Van Elslander Cancer Center at St. John Hospital and Medical Center</name>
      <address>
        <city>Grosse Pointe Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Regional Cancer Center at Mercy Hospital</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA - Maplewood</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute at Abbott - Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humphrey Cancer Center at North Memorial Outpatient Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422-2900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Clinic - River Campus</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital Cancer Care Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Cancer Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center at Singing River Hospital</name>
      <address>
        <city>Pascagoula</city>
        <state>Mississippi</state>
        <zip>39581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish West County Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - St. Peters</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic - Downtown</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Cancer Center at Good Samaritan Hospital</name>
      <address>
        <city>Kearney</city>
        <state>Nebraska</state>
        <zip>68848-1990</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Elizabeth Cancer Institute at Saint Elizabeth Regional Medical Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Estabrook Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renown Institute for Cancer at Renown Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Payson Center for Cancer Care at Concord Hospital</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care at Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>New Hampshire</state>
        <zip>03833</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elliot Regional Cancer Center at Elliot Hospital</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ University Hospital</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Phillip Citta Regional Cancer Center at Community Medical Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Cooper - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-5636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, PC at Albany Regional Cancer Care</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sands Cancer Center</name>
      <address>
        <city>Canandaigua</city>
        <state>New York</state>
        <zip>14424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's - Roosevelt Hospital Center - St.Luke's Division</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Hospital of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Radiation Oncology at Parkridge Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Cancer Center at Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Cancer Center at Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233-3549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of North Carolina - Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - MeritCare Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Cancer Center at Altru Hospital</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity CancerCare Center</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McDowell Cancer Center at Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Center for Cancer Care at Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309-2090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barberton Citizens Hospital</name>
      <address>
        <city>Barberton</city>
        <state>Ohio</state>
        <zip>44203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Cancer Center at Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710-1799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adena Regional Medical Center</name>
      <address>
        <city>Chillicothe</city>
        <state>Ohio</state>
        <zip>45601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles M. Barrett Cancer Center at University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center at Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center</name>
      <address>
        <city>Independence</city>
        <state>Ohio</state>
        <zip>44131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Cancer Center at Hillcrest Hospital</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest General Health Center</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHHS Chagrin Highlands Medical Center</name>
      <address>
        <city>Orange Village</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Mercy Hospital</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <zip>43616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Care, Incorporated</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flower Hospital Cancer Center</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anne Mercy Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHHS Westlake Medical Center</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Wooster</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at St. Francis Hospital</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Center - Eugene</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Radiation Oncology Center</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dale and Frances Hughes Cancer Center at Pocono Medical Center</name>
      <address>
        <city>East Stroudsburg</city>
        <state>Pennsylvania</state>
        <zip>18301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center - Erie</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Paoli Memorial Hospital</name>
      <address>
        <city>Paoli</city>
        <state>Pennsylvania</state>
        <zip>19301-1792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center at Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankford Hospital Cancer Center - Torresdale Campus</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Cancer Center at Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas - Faris Road</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas - Seneca</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gibbs Regional Cancer Center at Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center at Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrington Cancer Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA at Texas Cancer Center - Arlington South</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA at Harris Center HEB</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA at Texas Cancer Center - Denton South</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klabzuba Cancer Center at Harris Methodist Fort Worth Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Texas Cancer Center</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas - Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA at Texas Cancer Center - Sherman</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA at Texas Oncology Cancer Center Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jon and Karen Huntsman Cancer Center at Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center - Provo</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dixie Regional Medical Center - East Campus</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists at UCS Cancer Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Virginia Mason Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest - Spokane South</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theda Care Cancer Institute</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midelfort Clinic - Luther</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54703-1510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luther Midlelfort Hospital</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellin Memorial Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital Medical Center - Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital Regional Cancer Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Center for Cancer and Blood</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Cancer Care Center at Bay Area Medical Center</name>
      <address>
        <city>Marinette</city>
        <state>Wisconsin</state>
        <zip>54143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D.N. Greenwald Center</name>
      <address>
        <city>Mukwonago</city>
        <state>Wisconsin</state>
        <zip>53149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Saints Cancer Center at Wheaton Franciscan Healthcare</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Door County Cancer Center at Door County Memorial Hospital</name>
      <address>
        <city>Sturgeon Bay</city>
        <state>Wisconsin</state>
        <zip>54235-1495</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waukesha Memorial Hospital Regional Cancer Center</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverview UW Cancer Center at Riverview Hospital</name>
      <address>
        <city>Wisconsin Rapids</city>
        <state>Wisconsin</state>
        <zip>54494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre at Pasqua Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre at the University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <results_first_submitted>January 17, 2017</results_first_submitted>
  <results_first_submitted_qc>March 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2017</results_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation toxicity</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Radiation Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>60 Gy RT</title>
          <description>60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
        </group>
        <group group_id="P2">
          <title>74 Gy RT</title>
          <description>74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
        </group>
        <group group_id="P3">
          <title>60 Gy RT + Cetuximab</title>
          <description>60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
        </group>
        <group group_id="P4">
          <title>74 Gy RT + Cetuximab</title>
          <description>74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166">Subjects with data available for the primary analysis are considered to have completed the study.</participants>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="147"/>
                <participants group_id="P4" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="137"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eligible patients who did not withdraw consent.</population>
      <group_list>
        <group group_id="B1">
          <title>60 Gy RT</title>
          <description>60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
        </group>
        <group group_id="B2">
          <title>74 Gy RT</title>
          <description>74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
        </group>
        <group group_id="B3">
          <title>60 Gy RT + Cetuximab</title>
          <description>60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
        </group>
        <group group_id="B4">
          <title>74 Gy RT + Cetuximab</title>
          <description>74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="137"/>
            <count group_id="B4" value="100"/>
            <count group_id="B5" value="495"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="37" upper_limit="82"/>
                    <measurement group_id="B2" value="64" lower_limit="41" upper_limit="82"/>
                    <measurement group_id="B3" value="64" lower_limit="38" upper_limit="83"/>
                    <measurement group_id="B4" value="64" lower_limit="44" upper_limit="83"/>
                    <measurement group_id="B5" value="64" lower_limit="37" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.</description>
        <time_frame>Analysis occurs after 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
        <population>Eligible patients who did not withdraw consent; patients enrolled while high dose arms open to accrual are included in the RT comparison, patients enrolled while cetuximab arms open to accrual are included in the cetuximab comparison. See &quot;Limitations and Caveats&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Patients Receiving 60 Gy RT</title>
            <description>Combining patients from arms receiving 60 Gy radiation therapy (RT) (60 Gy RT and 60 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O2">
            <title>Combined Patients Receiving 74 Gy RT</title>
            <description>Combining patients from arms receiving 74 Gy RT (74 Gy RT and 74 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O3">
            <title>Combined Patients Receiving Cetuximab</title>
            <description>Combining patients from arms receiving Cetuximab (60 Gy RT + Cetuximab and 74 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O4">
            <title>Combined Patients From Arms Receiving No Cetuximab</title>
            <description>Combining patients from arms receiving No Cetuximab (60 Gy RT and 74 Gy RT</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.</description>
          <population>Eligible patients who did not withdraw consent; patients enrolled while high dose arms open to accrual are included in the RT comparison, patients enrolled while cetuximab arms open to accrual are included in the cetuximab comparison. See &quot;Limitations and Caveats&quot;.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="237"/>
                <count group_id="O4" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="24.1" upper_limit="36.9"/>
                    <measurement group_id="O2" value="20.3" lower_limit="17.7" upper_limit="25.0"/>
                    <measurement group_id="O3" value="25.0" lower_limit="20.2" upper_limit="30.5"/>
                    <measurement group_id="O4" value="24.0" lower_limit="19.8" upper_limit="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The trial was a two-by-two factorial design with radiation therapy dose as one treatment factor and cetuximab as the other. A log-rank test for each factor at one-sided α of 0.0125 (α of 0.0250 for both factors to account for multiple comparisons) would yield power of 80% to detect an improvement in median survival from 17.1 to 24 months after 339 deaths were reported out of 500 patients. For RT analysis, the comparison was arms 1 &amp; 3 vs arms 2 &amp; 4; for cetuximab, arms 1 &amp; 2 vs arms 3 &amp; 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
            <estimate_desc>Reference group = 60 gy</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The trial was a two-by-two factorial design with radiation therapy dose as one treatment factor and cetuximab as the other. A log-rank test for each factor at one-sided α of 0.0125 (α of 0.0250 for both factors to account for multiple comparisons) would yield power of 80% to detect an improvement in median survival from 17.1 to 24 months after 339 deaths were reported out of 500 patients. For RT analysis, the comparison was arms 1 &amp; 3 vs arms 2 &amp; 4; for cetuximab, arms 1 &amp; 2 vs arms 3 &amp; 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Reference level = cetuximab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>A failure for progression-free survival (PFS) is the first occurrence of local or regional progression, distant metastases, or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions. Time is measured from the date of randomization to the date of first failure. Patients without failure are censored at the date of last follow-up.</description>
        <time_frame>Analysis occurs after 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
        <population>Eligible patients who did not withdraw consent; patients enrolled while high dose arms open to accrual are included in the RT comparison, patients enrolled while cetuximab arms open to accrual are included in the cetuximab comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Patients Receiving 60 Gy RT</title>
            <description>Combining patients from arms receiving 60 Gy RT (60 Gy RT and 60 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O2">
            <title>Combined Patients Receiving 74 Gy RT</title>
            <description>Combining patients from arms receiving 74 Gy RT (74 Gy RT and 74 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O3">
            <title>Combined Patients Receiving Cetuximab</title>
            <description>Combining patients from arms receiving Cetuximab (60 Gy RT + Cetuximab and 74 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O4">
            <title>Combined Patients From Arms Receiving No Cetuximab</title>
            <description>Combining patients from arms receiving No Cetuximab (60 Gy RT and 74 Gy RT</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>A failure for progression-free survival (PFS) is the first occurrence of local or regional progression, distant metastases, or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions. Time is measured from the date of randomization to the date of first failure. Patients without failure are censored at the date of last follow-up.</description>
          <population>Eligible patients who did not withdraw consent; patients enrolled while high dose arms open to accrual are included in the RT comparison, patients enrolled while cetuximab arms open to accrual are included in the cetuximab comparison.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="237"/>
                <count group_id="O4" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="10.2" upper_limit="14.3"/>
                    <measurement group_id="O2" value="9.8" lower_limit="8.8" upper_limit="11.6"/>
                    <measurement group_id="O3" value="10.8" lower_limit="9.8" upper_limit="12.3"/>
                    <measurement group_id="O4" value="10.7" lower_limit="9.3" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Progression-free survival is estimated by the Kaplan-Meier method. Comparisons by RT level and by cetuximab assignment are performed separately and tested with a two-sided significance level of 0.05 for each comparison.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
            <estimate_desc>Reference level = 60 Gy</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Progression-free survival is estimated by the Kaplan-Meier method. Comparisons by RT level and by cetuximab assignment are performed separately and tested with a two-sided significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Reference level = cetuximab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local-regional Failure (Reported as Two-year Estimates)</title>
        <description>A failure for local-regional failure is the first occurrence of local or regional progression. Time is measured from the date of randomization to the date of first failure. Patients alive without local or regional failure at the time of last follow-up are censored. Patients who died without local or regional failure are considered as having competing risk at the time of death. Local-regional failure was estimated by the cumulative incidence method and 2 year estimates are reported.</description>
        <time_frame>Analysis occurs after 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
        <population>Eligible patients who did not withdraw consent; patients enrolled while high dose arms open to accrual are included in the RT comparison, patients enrolled while cetuximab arms open to accrual are included in the cetuximab comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Patients Receiving 60 Gy RT</title>
            <description>Combining patients from arms receiving 60 Gy RT (60 Gy RT and 60 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O2">
            <title>Combined Patients Receiving 74 Gy RT</title>
            <description>Combining patients from arms receiving 74 Gy RT (74 Gy RT and 74 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O3">
            <title>Combined Patients Receiving Cetuximab</title>
            <description>Combining patients from arms receiving Cetuximab (60 Gy RT + Cetuximab and 74 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O4">
            <title>Combined Patients From Arms Receiving No Cetuximab</title>
            <description>Combining patients from arms receiving No Cetuximab (60 Gy RT and 74 Gy RT</description>
          </group>
        </group_list>
        <measure>
          <title>Local-regional Failure (Reported as Two-year Estimates)</title>
          <description>A failure for local-regional failure is the first occurrence of local or regional progression. Time is measured from the date of randomization to the date of first failure. Patients alive without local or regional failure at the time of last follow-up are censored. Patients who died without local or regional failure are considered as having competing risk at the time of death. Local-regional failure was estimated by the cumulative incidence method and 2 year estimates are reported.</description>
          <population>Eligible patients who did not withdraw consent; patients enrolled while high dose arms open to accrual are included in the RT comparison, patients enrolled while cetuximab arms open to accrual are included in the cetuximab comparison.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="237"/>
                <count group_id="O4" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" lower_limit="35.7" upper_limit="49.0"/>
                    <measurement group_id="O2" value="48.4" lower_limit="41.5" upper_limit="55.3"/>
                    <measurement group_id="O3" value="47.1" lower_limit="40.6" upper_limit="53.6"/>
                    <measurement group_id="O4" value="40.7" lower_limit="34.2" upper_limit="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Local-regional failure was estimated by the cumulative incidence method. Comparisons by RT level and by cetuximab assignment are performed separately and tested with a two-sided significance level of 0.05 for each comparison.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Gray's test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>Reference level = 60 Gy</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Local-regional failure was estimated by the cumulative incidence method. Comparisons by RT level and by cetuximab assignment are performed separately and tested with a two-sided significance level of 0.05 for each comparison.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Gray's test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Reference level = cetuximab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 3-5 Esophagitis and Pneumonitis Adverse Events as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0</title>
        <description>Treatment-related esophagitis and pneumonitis were assessed graded using the CTCAE v3.0. Comparisons are only made between radiation therapy dosing levels because the cetuximab regimen was known to be safe in combination with radiation therapy.</description>
        <time_frame>Analysis occurs after 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
        <population>All eligible patients enrolled while the high dose arms were open, who did not withdraw consent.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Patients Receiving 60 Gy RT</title>
            <description>Combining patients from arms receiving 60 Gy RT (60 Gy RT and 60 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O2">
            <title>Combined Patients Receiving 74 Gy RT</title>
            <description>Combining patients from arms receiving 74 Gy RT (74 Gy RT and 74 Gy RT + Cetuximab)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3-5 Esophagitis and Pneumonitis Adverse Events as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0</title>
          <description>Treatment-related esophagitis and pneumonitis were assessed graded using the CTCAE v3.0. Comparisons are only made between radiation therapy dosing levels because the cetuximab regimen was known to be safe in combination with radiation therapy.</description>
          <population>All eligible patients enrolled while the high dose arms were open, who did not withdraw consent.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Esophagitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="4.3" upper_limit="11.7"/>
                    <measurement group_id="O2" value="20.8" lower_limit="15.5" upper_limit="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="3.5" upper_limit="10.3"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.0" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Esophagitis: Only those toxicities reported as possibly, probably, or definitely related to treatment were considered. The worst grade of esophagitis and the worst grade of pneumonitis at any time were classified by binary groupings of &lt; grade 3 and &gt;= grade 3. Comparisons were made using a two-sided chi-square test with a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PNEUMONITIS: Only those toxicities reported as possibly, probably, or definitely related to treatment were considered. The worst grade of esophagitis and the worst grade of pneumonitis at any time were classified by binary groupings of &lt; grade 3 and &gt;= grade 3. Comparisons were made using a two-sided chi-square test with a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2533</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Other Grade 3-5 Adverse Events as Assessed by NCI CTCAE v3.0</title>
        <description>Treatment-related adverse events other than esophagitis and pneumonitis were assessed graded using the CTCAE v3.0. Comparisons are only made between radiation therapy dosing levels because the cetuximab regimen was known to be safe in combination with radiation therapy.</description>
        <time_frame>Analysis occurs 50 months of accrual and an additional 18 months of follow-up, such that patients are followed at least 18 months from randomization.</time_frame>
        <population>All eligible patients enrolled while the high dose arms were open, who did not withdraw consent.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Patients Receiving 60 Gy RT</title>
            <description>Combining patients from arms receiving 60 Gy RT (60 Gy RT and 60 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O2">
            <title>Combined Patients Receiving 74 Gy RT</title>
            <description>Combining patients from arms receiving 74 Gy RT (74 Gy RT and 74 Gy RT + Cetuximab)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Other Grade 3-5 Adverse Events as Assessed by NCI CTCAE v3.0</title>
          <description>Treatment-related adverse events other than esophagitis and pneumonitis were assessed graded using the CTCAE v3.0. Comparisons are only made between radiation therapy dosing levels because the cetuximab regimen was known to be safe in combination with radiation therapy.</description>
          <population>All eligible patients enrolled while the high dose arms were open, who did not withdraw consent.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" lower_limit="68.8" upper_limit="80.7"/>
                    <measurement group_id="O2" value="77.8" lower_limit="71.5" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only those toxicities reported as possibly, probably, or definitely related to treatment were considered. The worst grade of of toxicity at any time was classified by a binary grouping of &lt; grade 3 and &gt;= grade 3. Comparisons were made using a two-sided chi-square test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death During or Within 30 Days of Discontinuation of Protocol Treatment</title>
        <description>Deaths regardless of cause and occuring during or within 30 days of discontinuation of protocol treatment were evaluated.</description>
        <time_frame>From start of treatment to 24 months.</time_frame>
        <population>Eligible patients who started study treatment and did not withdraw consent.</population>
        <group_list>
          <group group_id="O1">
            <title>60 Gy RT</title>
            <description>60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
          </group>
          <group group_id="O2">
            <title>74 Gy RT</title>
            <description>74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
          </group>
          <group group_id="O3">
            <title>60 Gy RT + Cetuximab</title>
            <description>60 gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
          </group>
          <group group_id="O4">
            <title>74 Gy RT + Cetuximab</title>
            <description>74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
          </group>
        </group_list>
        <measure>
          <title>Death During or Within 30 Days of Discontinuation of Protocol Treatment</title>
          <description>Deaths regardless of cause and occuring during or within 30 days of discontinuation of protocol treatment were evaluated.</description>
          <population>Eligible patients who started study treatment and did not withdraw consent.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="4.3"/>
                    <measurement group_id="O2" value="3.8" lower_limit="0.1" upper_limit="7.4"/>
                    <measurement group_id="O3" value="8.8" lower_limit="4.1" upper_limit="13.6"/>
                    <measurement group_id="O4" value="4.1" lower_limit="0.2" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Decline From Baseline to 3 Months in the Lung Cancer Subscale (LCS) of the Functional Assessment of the Cancer Therapy Trial Outcome Index (FACT-TOI).</title>
        <description>A decline of 2 points in the LCS from baseline to 3 months was considered a clinically meaningful change indicating a decline in quality of life. Comparisons are only made between radiation therapy dosing levels because the cetuximab regimen was known to be safe in combination with radiation therapy.</description>
        <time_frame>At baseline and 3 months.</time_frame>
        <population>Eligible patients who enrolled while the high dose arms were open, had baseline and 3 month assessments, and did not withdraw consent.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Patients Receiving 60 Gy RT</title>
            <description>Combining patients from arms receiving 60 Gy RT (60 Gy RT and 60 Gy RT + Cetuximab)</description>
          </group>
          <group group_id="O2">
            <title>Combined Patients Receiving 74 Gy RT</title>
            <description>Combining patients from arms receiving 74 Gy RT (74 Gy RT and 74 Gy RT + Cetuximab)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Decline From Baseline to 3 Months in the Lung Cancer Subscale (LCS) of the Functional Assessment of the Cancer Therapy Trial Outcome Index (FACT-TOI).</title>
          <description>A decline of 2 points in the LCS from baseline to 3 months was considered a clinically meaningful change indicating a decline in quality of life. Comparisons are only made between radiation therapy dosing levels because the cetuximab regimen was known to be safe in combination with radiation therapy.</description>
          <population>Eligible patients who enrolled while the high dose arms were open, had baseline and 3 month assessments, and did not withdraw consent.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="21.4" upper_limit="39.5"/>
                    <measurement group_id="O2" value="45.0" lower_limit="35.4" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FACT-TOI-LCS was assessed and changes from baseline to 3 months calculated and grouped using a 2 point decline as the threshold. Comparisons of decline vs no decline by RT level were from a Cochran-Mantel-Haenszel test and controlling for cetuximab assignment using a two-side significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0233</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-reported Swallowing Ability</title>
        <time_frame>From start of treatment to 24 months.</time_frame>
        <posting_date>08/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality-adjusted Survival Based on EuroQoL (EQ5D)-Derived Health Utility Score</title>
        <time_frame>From start of treatment to 24 months.</time_frame>
        <posting_date>08/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Tumor Markers With Overall Survival, Local-regional Failure, and QOL</title>
        <description>Biomarker data has not yet been obtained and therefore this outcome measure cannot yet be reported.</description>
        <time_frame>Analysis occurs after 339 deaths have been reported, estimated at 5.6 years from start of study, unless a futility bound is crossed prior to that.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prognostic and Predictive Effects of Gross Tumor Volume on Overall Survival</title>
        <time_frame>From randomization to date of death or last follow-up. Analysis occurs after 339 deaths have been reported.</time_frame>
        <posting_date>08/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prognostic Value of Pre-treatment Standardized Uptake Value (SUV) of Positron Emission Tomography (PET) Scan in Predicting Survival, Distant Metastasis, and Local-regional Control</title>
        <time_frame>From randomization to date of failure (either local or regional), death or last follow-up. Analysis occurs after 339 deaths have been reported.</time_frame>
        <posting_date>08/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Subjects experiencing more than one of a given adverse event are counted only once for that adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>60 Gy RT</title>
          <description>60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
        </group>
        <group group_id="E2">
          <title>74 Gy RT</title>
          <description>74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin</description>
        </group>
        <group group_id="E3">
          <title>60 Gy RT + Cetuximab</title>
          <description>60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
        </group>
        <group group_id="E4">
          <title>74 Gy RT + Cetuximab</title>
          <description>74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Cardiac pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Premature ventricular contractions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Acquired tracheo-esophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Duodenal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophageal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophageal mucositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pain [other]</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bladder infection [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bone infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bronchitis [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bronchitis [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bronchitis [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Catheter related infection [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Catheter related infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Catheter related infection [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Device related infection [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Endocarditis infective [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Endocarditis infective [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gingival infection [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Gingival infection [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Infection [other]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Infectious colitis [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Penile infection [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Peritoneal infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pleural infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Sepsis [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Sepsis [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Sepsis [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Skin infection [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Skin infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Soft tissue infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Urinary tract infection [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Urinary tract infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Urinary tract infection [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Wound infection [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Wound infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Intraoperative musculoskeletal injury - Joint</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Radiation recall reaction (dermatologic)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusing capacity decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis lower limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bronchial fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pharyngeal examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Respiratory tract hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pain [other]</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection [other]</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Radiation recall reaction (dermatologic)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Cetuximab arms were added after the study opened, therefore the first 34 patients were excluded from cetuximab analysis. High dose RT arms closed early (at n=474), therefore later patients enrolled to low dose RT arm were excluded from RT analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Wendy Seiferheld, M.S.</name_or_title>
      <organization>NRG Oncology</organization>
      <email>seiferheldw@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

